Journal
BIOTECHNOLOGY AND BIOENGINEERING
Volume 82, Issue 3, Pages 321-329Publisher
WILEY
DOI: 10.1002/bit.10574
Keywords
viral clearance; monoclonal antibodies; recombinant proteins; low pH unit operations
Categories
Ask authors/readers for more resources
Viral safety is a predominant concern for monoclonal antibodies (mAbs) and other recombinant proteins (RPs) with pharmaceutical applications. Certain commercial purification modules, such as nanofiltration and low-pH inactivation, have been observed to reliably clear greater than 4 log(10) of large enveloped viruses, including enclogenous retrovirus. The concept of bracketed generic clearance has been proposed for these steps if it could be prospectively demonstrated that viral log(10) reduction value (LRV) is not impacted by operating parameters that can vary, within a reasonable range, between commercial processes. In the case of low-pH inactivation, a common step in mAb purification processes employed after protein A affinity chromatography, these parameters would include pH, time and temperature of incubation, the content of salts, protein concentration, aggregates, impurities, model protein pI, and buffer composition. In this report, we define bracketed generic clearance conditions, using a prospectively defined bracket/matrix approach, where low-pH inactivation consistently achieves greater than or equal to4.6 log clearance of xenotropic murine leukemia virus (X-MLV), a model for rodent enclogenous retrovirus. The mechanism of retrovirus inactivation by low-pH treatment was also investigated. (C) 2003 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available